Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-46833
Graham, J; Banaschewski, T; Buitelaar, J; Coghill, D; Danckaerts, M; Dittmann, R W; Döpfner, M; Hamilton, R; Hollis, C; Holtmann, M; Hulpke-Wette, M; Lecendreux, M; Rosenthal, E; Rothenberger, A; Santosh, P; Sergeant, J; Simonoff, E; Sonuga-Barke, E; Wong, I C K; Zuddas, A; Steinhausen, H C; Taylor, E (2011). European guidelines on managing adverse effects of medication for ADHD. European Child & Adolescent Psychiatry, 20(1):17-37.
|PDF - Registered users only|
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > Center for Child and Adolescent Psychiatry|
|DDC:||610 Medicine & health|
|Deposited On:||25 Feb 2011 17:07|
|Last Modified:||27 Nov 2013 21:55|
|Citations:||Web of Science®. Times cited: 48|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page